Foresite Capital
Overview
Foresite Capital is a multi-stage healthcare and life sciences investment firm that uses a data science-driven approach to invest in companies at the intersection of technology and biotechnology across their full lifecycle.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Altos Labs | Jan 2022 | VC Round | Co-investor |
| Treeline Biosciences | Apr 2021 | Series A | Co-investor |
| Xaira Therapeutics | Apr 2024 | Series A | Lead |
| Insitro | Mar 2021 | Series C | Co-investor |
| Parabilis Medicines | Jan 2026 | Series F | Co-investor |
For institutional investors. Book with your work email.
Key People
Cynthia Carpenter
Executive Associate to CEO and Founder, Jim Tananbaum
Jim Tananbaum
Founder And CEO
Michael Rome
Managing Director
Travis Young
Venture Partner
Cindy Xiong
Partner
Hyung Chun
Partner
Lovely Rose E.
Partner
Beata Lewandowska
Vice President Partner
Ekaterina K
Partner Deep Tech Ventures Board Member
Deepak S. Atri
Principal
Shoman Kasbekar
Principal
Matt Dyer 🇺🇦
Executive Advisor Investor
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Foresite Capital based?
Foresite Capital is headquartered in San Francisco, California, United States.
When was Foresite Capital founded?
Foresite Capital was founded in 2011.
How many portfolio companies does Foresite Capital have?
Foresite Capital has 81 portfolio companies in Caplight's dataset.
What are some companies in Foresite Capital's portfolio?
Portfolio companies visible on Caplight include Altos Labs, Treeline Biosciences, Xaira Therapeutics, Insitro, Parabilis Medicines.
What was Foresite Capital's most recent investment shown here?
Foresite Capital's most recent investment in this portfolio sample was in Parabilis Medicines in 2026.
What sectors does Foresite Capital focus on?
Foresite Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Frontier & Industrial Tech, AI, Data & Cloud Infrastructure, Energy & Sustainability, Enterprise Software, Healthcare & Life Sciences, Enterprise Software, AI, Data & Cloud Infrastructure, AI, Data & Cloud Infrastructure, AI, Data & Cloud Infrastructure, Consumer & Commerce, Enterprise Software, Enterprise Software, AI, Data & Cloud Infrastructure, AI, Data & Cloud Infrastructure, Enterprise Software, AI, Data & Cloud Infrastructure, AI, Data & Cloud Infrastructure, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, AI, Data & Cloud Infrastructure, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, Enterprise Software, Consumer & Commerce, AI, Data & Cloud Infrastructure, Consumer & Commerce, Frontier & Industrial Tech, Enterprise Software.
What company stages does Foresite Capital focus on?
Foresite Capital typically invests at the MultiStage stage.
What is Foresite Capital's AUM?
Foresite Capital's assets under management are estimated between $1.0B and $10.0B.